PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26221F0351Jynarque medication — Otsuka America Pharmaceutical, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Aug 22, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

262-Network Contract Office 22 (36C262)

Awarding office

Otsuka America Pharmaceutical, Inc

Recipient

Aug 22, 2022

PoP end

$12K

Obligated

$281K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Otsuka America Pharmaceutical, Inc — $90

Contract facts

Federal

Contract number36C26221F0351

Also listed as36C262-21-F-0351

Also listed as36F79720D0099-36C26221F0351

Agency262-Network Contract Office 22 (36C262)

Awarding office262-Network Contract Office 22 (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentOtsuka America Pharmaceutical, Inc

CAGE0ZHV7

UEIQKABLBMA8FT9

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0099

Place of performanceLONG BEACH CA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJul 1, 2021

PoP end (current)Aug 22, 2022

Obligated$12K

Current value$281K

Potential value$281K

JYNARQUE MEDICATION is a federal award for 262-Network Contract Office 22 (36C262) held by Otsuka America Pharmaceutical, Inc. Estimated value $281K ($12K obligated). Current period of performance ends Aug 22, 2022. Last award drew 1 bidder. Place of performance: LONG BEACH CA.

Recompete timing

Public

● Past PoP end (1460 days ago)

Current PoP ended Aug 22, 2022 (1460 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26221F0351?

36C26221F0351 (Jynarque medication) is a 262-Network Contract Office 22 (36C262) award with a potential value of $281K, currently held by Otsuka America Pharmaceutical, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-21-F-0351?

36C262-21-F-0351 is the dashed form of PIID 36C26221F0351 (Jynarque medication), held by Otsuka America Pharmaceutical, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26221F0351?

262-Network Contract Office 22 (36C262) awarded 36C26221F0351 to Otsuka America Pharmaceutical, Inc (potential $281K).

Who is the incumbent on 36C26221F0351?

Otsuka America Pharmaceutical, Inc is the incumbent. The current period of performance ends Aug 22, 2022.

When does Otsuka America Pharmaceutical, Inc’s 36C26221F0351 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 22, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 22, 2022 · refreshed monthly